Disc Medicine (NASDAQ:IRON) Stock Price Down 3% – Time to Sell?

by · The Markets Daily

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) was down 3% on Friday . The company traded as low as $61.07 and last traded at $61.07. Approximately 29,558 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 345,359 shares. The stock had previously closed at $62.95.

Wall Street Analyst Weigh In

IRON has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Jefferies Financial Group started coverage on Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective for the company. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a research report on Tuesday, November 5th. Wells Fargo & Company began coverage on Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price target on the stock. Finally, Scotiabank upped their price target on shares of Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 5th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Disc Medicine currently has an average rating of “Buy” and a consensus target price of $87.50.

Check Out Our Latest Stock Analysis on Disc Medicine

Disc Medicine Price Performance

The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -16.28 and a beta of 0.76. The business has a fifty day moving average of $58.50 and a 200 day moving average of $50.33.

Disc Medicine (NASDAQ:IRON – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15. On average, analysts expect that Disc Medicine, Inc. will post -4.05 EPS for the current year.

Insider Buying and Selling

In other Disc Medicine news, Director William Richard White sold 1,957 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $64.63, for a total value of $126,480.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John D. Quisel sold 12,791 shares of Disc Medicine stock in a transaction on Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the transaction, the chief executive officer now directly owns 72,065 shares in the company, valued at approximately $4,757,010.65. This represents a 15.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,627 shares of company stock valued at $2,883,150 over the last three months. Company insiders own 4.24% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank lifted its holdings in shares of Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares in the last quarter. Quest Partners LLC bought a new position in Disc Medicine in the third quarter valued at approximately $131,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Disc Medicine in the second quarter valued at approximately $129,000. Finally, Quantbot Technologies LP bought a new stake in shares of Disc Medicine during the third quarter worth $146,000. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Featured Articles